Tieshi Zhu: NHANES Study Reveals Significant Mortality Risk With Clopidogrel Monotherapy After PCI
Platelets Journal shared an insightful post on LinkedIn:
“How does clopidogrel monotherapy compare to aspirin after PCI and DAPT?
Building on a recent Korean study that highlighted the efficacy of clopidogrel monotherapy following percutaneous coronary intervention (PCI) and standard dual antiplatelet therapy (DAPT), Zhu et al. (2025) conducted a retrospective analysis of the U.S. NHANES 1999–2018 cohort to compare all-cause mortality between clopidogrel and aspirin monotherapy under similar conditions.
Contrary to previous findings in Asian populations, the authors found that clopidogrel monotherapy was associated with increased risks of all-cause mortality, cardiac mortality, and stroke compared to aspirin monotherapy.”
Read the full article here:
Article: Clopidogrel monotherapy is associated with higher mortality risk compared to aspirin: a retrospective analysis of NHANES 1999–2018
Authors: Tieshi Zhu, Yong He, Yuzhang Bei, Hui Mai, and Le Zhao
Follow the newest developments in clotting science with Hemostasis Today.
-
Oct 13, 2025, 03:53Ganesh Mohan is Organising a Webinar to Improve Awareness About Thrombophilia on World Thrombosis Day
-
Oct 13, 2025, 02:47Thomas Reiser: Don't Miss This ISTH Research Recap with Robert Sidonio, Cedric Hermans and Michael Makris
-
Oct 12, 2025, 01:30Elvira Grandone: Pregnancy and VTE - Still A Relevant Cause of Maternal Mortality
-
Oct 12, 2025, 01:29Emilia Arturo: Consider Submitting the Paper and Its Reviews for a Second Look Rapid Response From One of These Blood Journals
-
Oct 12, 2025, 01:22Christina (Tina) P.: APS is Responsible for 1 in 3 Strokes in People Under 50 and The N1 Cause of Stroke in Young People
-
Oct 13, 2025, 03:32Wolfgang Miesbach: This Study from Children's Hospital of Philadelphia Provides Crucial Insights Into Elevidys
-
Oct 13, 2025, 02:43Lukas Meyer and Colleagues on Reperfusion-dependent Treatment Effects of Thrombectomy in Large Ischemic Infarcts
-
Oct 12, 2025, 10:14Hatim Lokhandwala: Landmark HI-PRO Trial Redefines VTE Treatment Guidelines
-
Oct 12, 2025, 01:32Camila V. Blair and Colleagues on The Association of CAD by Coronary CT Angiography and Cardiovascular Outcomes in Psoriatic Disease
-
Oct 12, 2025, 01:26Caroline Dixon and Colleagues on LMWH Dosing to Reduce The Risk of VTE in Pregnant Women With Inherited ATD
-
Oct 13, 2025, 02:46Flora Peyvandi: First Proposed Blood Test for Chronic Fatigue Syndrome - What Scientists Think
-
Oct 13, 2025, 02:44Silvio Maresca: Honored to be part of this international research project - ThrombUS+
-
Oct 10, 2025, 12:25Robert Lewis: T Cells Are Wonderful - But They Can't Do Everything
-
Oct 9, 2025, 13:03Peter Graves: When the Bleeding Does Not Stop
-
Oct 8, 2025, 12:44Bobur Kholikov: Thrombosis Diagnostics with YHLO
-
Oct 13, 2025, 03:44Jorge Monge: It Was An Honor to Take Part in the 3rd EBA Workshop on Rare Blood Provision
-
Oct 13, 2025, 03:15Arun V. J: They Chose Death Over A Blood Transfusion — And Here’s Why I Stopped Judging Them
-
Oct 13, 2025, 03:13Rahaf Ajaj: The Persistent Gender Gap in Nobel Prizes - A Call for Greater Inclusion
-
Oct 13, 2025, 02:50Emmanuel J Favaloro: Again Promoting World Thrombosis Day - October 13
-
Oct 12, 2025, 01:33Stefan Galisch: This Week We Celebrate IPAW– A Global Initiative That Raises Awareness of The Life-saving Importance of Plasma Donation